THE RISKS OF CONCURRENT TREATMENT WITH TENOFOVIR AND AMINOGLYCOSIDES IN PATIENTS WITH HIV-ASSOCIATED TUBERCULOSIS.
作者信息
Kenyon Chris, Wearne Nicci, Burton Rosie, Meintjes Graeme
机构信息
Department of Medicine, G F Jooste Hospital, Cape Town.
出版信息
South Afr J HIV Med. 2011;12(1):43-45. doi: 10.4102/sajhivmed.v12i1.214.
Abstract
摘要
相似文献
1
THE RISKS OF CONCURRENT TREATMENT WITH TENOFOVIR AND AMINOGLYCOSIDES IN PATIENTS WITH HIV-ASSOCIATED TUBERCULOSIS.HIV 相关结核病患者中同时使用替诺福韦和氨基糖苷类药物进行治疗的风险
South Afr J HIV Med. 2011;12(1):43-45. doi: 10.4102/sajhivmed.v12i1.214.
2
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.拉替拉韦治疗 HIV 和结核分枝杆菌合并感染患者（ANRS 12 180 Reflate TB）：一项多中心、2 期、非对照、开放标签、随机试验。
Lancet Infect Dis. 2014 Jun;14(6):459-67. doi: 10.1016/S1473-3099(14)70711-X. Epub 2014 Apr 9.
3
Broadening access to tenofovir alafenamide for the treatment and prevention of HIV-1 infection.扩大替诺福韦艾拉酚胺在治疗和预防 HIV-1 感染方面的应用。
Expert Rev Clin Pharmacol. 2023 Jul-Dec;16(10):939-957. doi: 10.1080/17512433.2023.2251387. Epub 2023 Sep 7.
4
Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.依非韦伦、替诺福韦和恩曲他滨联合一线抗结核治疗用于坦桑尼亚结核合并艾滋病患者：一项药代动力学和安全性研究。
Antivir Ther. 2013;18(1):105-13. doi: 10.3851/IMP2413. Epub 2012 Oct 5.
5
Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.替诺福韦酯/恩曲他滨和依非韦伦联合治疗治疗结核病的 HIV 感染患者：ANRS 129 BKVIR 试验。
J Antimicrob Chemother. 2016 Mar;71(3):783-93. doi: 10.1093/jac/dkv384. Epub 2015 Dec 17.
6
Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan.在 HIV-1 感染患者中，从富马酸替诺福韦二吡呋酯转换为替诺福韦艾拉酚胺治疗的结果：日本的一项真实世界研究。
HIV Med. 2021 Jul;22(6):457-466. doi: 10.1111/hiv.13061. Epub 2021 Mar 15.
7
Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: real-world data.在 HIV 阳性患者中，艾维雷韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺复方制剂的疗效和安全性：真实世界数据。
Int J STD AIDS. 2021 May;32(6):562-569. doi: 10.1177/0956462420983692. Epub 2021 Feb 18.
8
Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.体重较轻对 HIV 感染患者替诺福韦相关肾功能障碍的影响：日本患者的回顾性队列研究。
PLoS One. 2011;6(7):e22661. doi: 10.1371/journal.pone.0022661. Epub 2011 Jul 25.
9
Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir-based antiretroviral therapy.服用依非韦伦和多替拉韦利匹韦林基于的抗逆转录病毒治疗的人群中尿替诺福韦和干血斑替诺福韦二磷酸浓度与病毒血症。
AIDS. 2024 Apr 1;38(5):697-702. doi: 10.1097/QAD.0000000000003818. Epub 2024 Jan 8.
10
Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.使用替诺福韦酯治疗的有抗逆转录病毒治疗经验的患者中HIV-1的基因型和表型分析。
AIDS. 2002 Jun 14;16(9):1227-35. doi: 10.1097/00002030-200206140-00004.
引用本文的文献
1
Renal proximal tubulopathy in an HIV-infected patient treated with tenofovir alafenamide and gentamicin: a case report.替诺福韦艾拉酚胺和庆大霉素治疗的 HIV 感染患者的肾近端小管病变：病例报告。
BMC Nephrol. 2020 Aug 12;21(1):339. doi: 10.1186/s12882-020-01981-9.
2
Safety implications of combined antiretroviral and anti-tuberculosis drugs.抗逆转录病毒和抗结核药物联合使用的安全性问题。
Expert Opin Drug Saf. 2020 Jan;19(1):23-41. doi: 10.1080/14740338.2020.1694901. Epub 2019 Dec 6.
3
Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatment.氨基糖苷类药物耐药结核病治疗中耳毒性的不良结局途径。
Arch Toxicol. 2019 May;93(5):1385-1399. doi: 10.1007/s00204-019-02407-8. Epub 2019 Apr 8.
4
Aminoglycoside-induced Hearing Loss Among Patients Being Treated for Drug-resistant Tuberculosis in South Africa: A Prediction Model.南非耐多药结核病治疗患者中氨基糖苷类诱导性听力损失：预测模型。
Clin Infect Dis. 2020 Feb 14;70(5):917-924. doi: 10.1093/cid/ciz289.
5
Approach to acute kidney injury in HIV-infected patients in South Africa.南非HIV感染患者急性肾损伤的处理方法
South Afr J HIV Med. 2017 Nov 28;18(1):714. doi: 10.4102/sajhivmed.v18i1.714. eCollection 2017.
6
Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients.耐多药结核病患者中期治疗结果不佳的预测因素。
BMC Infect Dis. 2017 Sep 29;17(1):655. doi: 10.1186/s12879-017-2746-5.
7
Integrated therapy for HIV and tuberculosis.艾滋病病毒与结核病的综合治疗
AIDS Res Ther. 2016 May 12;13:22. doi: 10.1186/s12981-016-0106-y. eCollection 2016.
8
Evaluation of adverse drug reactions in HIV positive patients in a tertiary care hospital.一家三级护理医院中HIV阳性患者药物不良反应的评估。
Perspect Clin Res. 2015 Jan-Mar;6(1):34-8. doi: 10.4103/2229-3485.148808.
9
Impact of ART on TB case fatality stratified by CD4 count for HIV-positive TB patients in Cape Town, South Africa (2009-2011).南非开普敦地区 CD4 计数分层下抗逆转录病毒治疗对 HIV 阳性结核病患者结核病病死率的影响（2009-2011 年）。
J Acquir Immune Defic Syndr. 2014 Aug 15;66(5):487-94. doi: 10.1097/QAI.0000000000000201.
10
Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review.资源有限环境下 HIV 相关结核病的管理：现状综述。
BMC Med. 2013 Dec 2;11:253. doi: 10.1186/1741-7015-11-253.
本文引用的文献
1
Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.系统评价和荟萃分析：替诺福韦酯二吡呋酯在 HIV 感染患者中的肾脏安全性。
Clin Infect Dis. 2010 Sep 1;51(5):496-505. doi: 10.1086/655681.
2
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.估算肾小球滤过率、慢性肾脏病与 HIV 阳性患者的抗反转录病毒药物使用。
AIDS. 2010 Jul 17;24(11):1667-78. doi: 10.1097/QAD.0b013e328339fe53.
3
Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir.在接受替诺福韦治疗的 HIV 患者中，尽管肾小球功能未受损，但存在肾脏管状异常。
AIDS. 2009 Mar 27;23(6):689-96. doi: 10.1097/QAD.0b013e3283262a64.
4
Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents.二线抗结核药物的药理学以及与抗逆转录病毒药物相互作用的可能性。
AIDS. 2009 Feb 20;23(4):437-46. doi: 10.1097/qad.0b013e328326ca50.
5
Genetic analysis of interactions with eukaryotic rRNA identify the mitoribosome as target in aminoglycoside ototoxicity.与真核生物核糖体RNA相互作用的遗传分析确定线粒体核糖体是氨基糖苷类耳毒性的靶点。
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20888-93. doi: 10.1073/pnas.0811258106. Epub 2008 Dec 22.
6
Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.非洲开始接受抗逆转录病毒治疗的HIV感染成人的严重肾功能不全及与肾功能损害相关的危险因素。
Clin Infect Dis. 2008 Apr 15;46(8):1271-81. doi: 10.1086/533468.
7
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.富马酸替诺福韦二吡呋酯治疗成人HIV感染的安全性：头4年
AIDS. 2007 Jun 19;21(10):1273-81. doi: 10.1097/QAD.0b013e3280b07b33.
8
Tenofovir-induced kidney injury.替诺福韦引起的肾损伤。
Expert Opin Drug Saf. 2007 Mar;6(2):155-64. doi: 10.1517/14740338.6.2.155.
9
10
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.替诺福韦酯、恩曲他滨和依非韦伦与齐多夫定、拉米夫定和依非韦伦治疗HIV的比较
N Engl J Med. 2006 Jan 19;354(3):251-60. doi: 10.1056/NEJMoa051871.
Zotero 插件